Leerink Swann initiated coverage on Intra-Cellular Therapies (NASDAQ: ITCI) with an Outperform rating and a price target of $34.00.

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $15.98 yesterday.